NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price, Forecast & News

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.41) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.48) by $0.07. The firm had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.38 million. Syndax Pharmaceuticals had a negative net margin of 4,013.45% and a negative return on equity of 110.20%. View Syndax Pharmaceuticals' Earnings History.

Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syndax Pharmaceuticals.

6 brokers have issued 1 year price targets for Syndax Pharmaceuticals' stock. Their forecasts range from $5.00 to $19.00. On average, they expect Syndax Pharmaceuticals' share price to reach $14.20 in the next year. This suggests a possible upside of 101.7% from the stock's current price. View Analyst Price Targets for Syndax Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syndax Pharmaceuticals.

News headlines about SNDX stock have trended very positive this week, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syndax Pharmaceuticals earned a news impact score of 4.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Syndax Pharmaceuticals.

Syndax Pharmaceuticals saw a increase in short interest in December. As of December 13th, there was short interest totalling 594,700 shares, an increase of 12.5% from the November 28th total of 528,700 shares. Based on an average daily trading volume, of 147,900 shares, the short-interest ratio is presently 4.0 days. Currently, 2.9% of the shares of the stock are short sold. View Syndax Pharmaceuticals' Current Options Chain.

Some companies that are related to Syndax Pharmaceuticals include ZIOPHARM Oncology (ZIOP), Dova Pharmaceuticals (DOVA), Vanda Pharmaceuticals (VNDA), Eagle Pharmaceuticals (EGRX), Stoke Therapeutics (STOK), CannTrust (CNTTF), Frequency Therapeutics (FREQ), ANI Pharmaceuticals (ANIP), Collegium Pharmaceutical (COLL), Cytokinetics (CYTK), Basilea Pharmaceutica (BPMUF), Flexion Therapeutics (FLXN), Akero Therapeutics (AKRO), Emisphere Technologies (EMIS) and Retrophin (RTRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include Opko Health (OPK), Exelixis (EXEL), TherapeuticsMD (TXMD), Idera Pharmaceuticals (IDRA), Cara Therapeutics (CARA), Proteostasis Therapeutics (PTI), Verastem (VSTM), Clearside Biomedical (CLSD), Progenics Pharmaceuticals (PGNX) and TG Therapeutics (TGTX).

(SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Syndax Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Campbell & CO Investment Adviser LLC (0.17%). Company insiders that own Syndax Pharmaceuticals stock include Briggs Morrison, Michael L Meyers and Peter Ordentlich. View Institutional Ownership Trends for Syndax Pharmaceuticals.

SNDX stock was acquired by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. Company insiders that have bought Syndax Pharmaceuticals stock in the last two years include Briggs Morrison and Michael L Meyers. View Insider Buying and Selling for Syndax Pharmaceuticals.

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SNDX stock can currently be purchased for approximately $7.04.

Syndax Pharmaceuticals has a market capitalization of $191.07 million and generates $1.52 million in revenue each year. The company earns $-73,960,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Syndax Pharmaceuticals employs 38 workers across the globe.View Additional Information About Syndax Pharmaceuticals.

The official website for Syndax Pharmaceuticals is http://www.syndax.com/.

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]